Loading...
Please wait, while we are loading the content...
Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes.
| Content Provider | Europe PMC |
|---|---|
| Author | Epistola, Raisa Sperandio, Rubens Wainberg, Zev Iqbal, Syma Chao, Joseph |
| Copyright Year | 2023 |
| Abstract | AbstractEsophagogastric cancers are aggressive malignancies, with poor prognosis despite current standard-of-care therapies. PD-1 inhibitors are a newer class of antitumor agents with the potential to improve outcomes among appropriately selected patients. This review provides an overview of the key trials that have guided the use of PD-1 and PD-L1 inhibitors in the refractory and first-line settings. We highlight recent studies investigating the role of genomic classification in predicting therapeutic activity of PD-1 inhibitors. In addition, there is a discussion of the use of different scoring systems and criteria to determine PD-L1 positivity, the impact on the therapeutic use of immune checkpoint inhibition with anti-PD-1 agents, and the controversies in current methods of PD-L1 testing and their implications in patient selection for anti-PD-1 therapy. |
| Page Count | 11 |
| Volume Number | 15 |
| PubMed Central reference number | PMC10032141 |
| PubMed reference number | 36969544 |
| Journal | Cancer Management and Research [Cancer Manag Res] |
| e-ISSN | 11791322 |
| DOI | 10.2147/CMAR.S341468 |
| Language | English |
| Publisher | Dove |
| Publisher Date | 2023-03-18 |
| Access Restriction | Open |
| Rights License | This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). © 2023 Epistola et al. |
| Subject Keyword | immunotherapy immune checkpoint inhibition PD-L1 gastric cancer gastroesophageal junction cancer |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology |
